Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic Full Text
Vascular Health and Risk Management,  Clinical Article

Volpe M et al. – The availability of these fixed–dose combinations should lead to improvement in blood pressure control and aid compliance with long–term therapy, optimizing the management of this chronic condition.

  • Hypertension is a growing global health problem, and is predicted to affect 1.56 billion people by 2025.
  • Treatment remains suboptimal, with control of blood pressure achieved in only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to achieve recommended blood pressure goals.
  • To improve blood pressure control, the European hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin–converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) and/or thiazide diuretics.
  • The rationale for this strategy is based, in part, on their different effects on the renin–angiotensin system, which improves antihypertensive efficacy.
  • Data from a large number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or hydrochlorothiazide (HCTZ).
  • Combining two different classes of antihypertensive drugs has an additive effect on lowering of blood pressure, and does not increase adverse events, with the ARBs showing a tolerability advantage over the ACEIs.
  • Among the different ARBs, olmesartan medoxomil is available as a dual fixed–dose combination with either amlodipine or HCTZ, and the increased blood pressure–lowering efficacy of these two combinations is proven.
  • Triple therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin–angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination according to the European guidelines.
  • Olmesartan, amlodipine, and HCTZ are available as a triple fixed–dose combination, and significant blood pressure reductions have been observed with this regimen compared with the possible dual combinations.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Medical Student

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Medical Student Articles

Indexed Journals in Medical Student: Academic Medicine, BMC Medical Education, Medical Teachermore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List